ストックスクリーナーアプリを入手
0.6645
2.01%
0.0131
前日終値:
$0.6514
開ける：
$0.6428
24時間の取引高:
2.83M
Relative Volume:
0.27
時価総額：
$65.11M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-11.78%
1か月 パフォーマンス:
-35.49%
6か月 パフォーマンス:
-82.28%
1年 パフォーマンス:
-77.70%
1日の値動き範囲:
$0.64
$0.6898
1週間の範囲:
$0.64
$0.7699
52週間の値動き範囲:
$0.64
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
名前
Atyr Pharma Inc
セクター
電話
(858) 731-8389
住所
10240 SORRENTO VALLEY ROAD, SAN DIEGO
ATYR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.6645 | 63.83M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | 開始されました | Leerink Partners | Outperform |
| 2025-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-04 | 開始されました | Wells Fargo | Overweight |
| 2024-09-05 | 開始されました | Jefferies | Buy |
| 2023-07-05 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-10-12 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-09-21 | 開始されました | Piper Sandler | Overweight |
| 2021-05-10 | 開始されました | Laidlaw | Buy |
| 2020-08-17 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 開始されました | ROTH Capital | Buy |
| 2020-03-02 | 開始されました | Oppenheimer | Outperform |
| 2018-02-14 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2017-09-07 | 開始されました | Piper Jaffray | Overweight |
| 2016-12-13 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2015-12-16 | 開始されました | Citigroup | Neutral |
| 2015-06-01 | 開始されました | Citigroup | Buy |
| 2015-06-01 | 開始されました | JP Morgan | Overweight |
すべてを表示
Atyr Pharma Inc (ATYR) 最新ニュース
ATyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - MarketScreener
Class Action Lawsuit Alert: Levi & Korsinsky Reminds aTyr Pharma, Inc. (ATYR) Investors of December 8, 2025 Deadline - ACCESS Newswire
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as - GlobeNewswire
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug’s Efficacy Moves Forward -- Hagens Berman - GlobeNewswire Inc.
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - PR Newswire
ATyr Pharma, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsATYR - MarketScreener
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
aTyr Pharma, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your RightsATYR - NewMediaWire
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - GlobeNewswire
ATyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman - MarketScreener
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Pharma, Inc. LawsuitATYR - PR Newswire
Why analysts maintain buy rating on aTyr Pharma Inc. (471A) stockPortfolio Risk Summary & Free Technical Pattern Based Buy Signals - newser.com
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Published on: 2025-11-19 21:36:05 - newser.com
Is aTyr Pharma Inc. (471A) stock inflation resilientProduct Launch & Low Drawdown Momentum Trade Ideas - newser.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - MarketScreener
Class Action Filed Against aTyr Pharma, Inc. (ATYR) Seeking Recovery for Investors – Contact ... - Bluefield Daily Telegraph
Class Action Filed Against aTyr Pharma, Inc. (ATYR) Seeking Recovery for Investors – Contact The Gross Law Firm - GlobeNewswire
How big funds are accumulating aTyr Pharma Inc. (471A) stock2025 Buyback Activity & Daily Profit Maximizing Trade Tips - newser.com
Lost Money on aTyr Pharma, Inc. (ATYR)? Contact Levi & Korsinsky to Join Class Action Before December 8, 2025 - The Globe and Mail
2025-11-18 | ATYR LAWSUIT ALERT: Levi & Korsinsky Notifies aTyr Pharma, Inc. InvestorsLead Plaintiff Deadline December 8, 2025 | NDAQ:ATYR | Press Release - Stockhouse
ATYR INVESTOR NOTICE: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman - PR Newswire
Wall Street analysts’ outlook for Atyr Pharma Inc (ATYR) - Setenews
DEADLINE ALERT for MRX, ATYR, and WPP: The Law Offices of - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, LEADING INVESTOR COUNSEL, Encourages aTyr Pharma, - GlobeNewswire
Shareholders SueWallSt in New Class Action Against aTyr Pharma, Inc.Act Now - Nasdaq
Bragar Eagel & Squire, P.C. Reminds Stockholders of aTyr, - GlobeNewswire
Investors who lost money on aTyr Pharma, Inc.(ATYR) should contact Levi & Korsinsky about ... - Bluefield Daily Telegraph
Investors who lost money on aTyr Pharma, Inc.(ATYR) should - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - MarketScreener
Deadline Alert: aTyr Pharma Inc. (ATYR) Shareholders Who - GlobeNewswire
Shareholders of aTyr Pharma, Inc. Should Contact The Gross Law F - GuruFocus
Shareholders of aTyr Pharma, Inc. Should Contact The Gross Law Firm Before December 8, 2025 to Discuss Your RightsATYR - PR Newswire
ATYR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that aTyr Pharma, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Will aTyr Pharma Inc. stock maintain growth story2025 Market Trends & Accurate Buy Signal Alerts - newser.com
Will aTyr Pharma Inc. bounce back from current support2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - newser.com
Is aTyr Pharma Inc. (471A) stock a top dividend aristocrat candidateJobs Report & Weekly Consistent Profit Watchlists - newser.com
Does aTyr Pharma Inc. fit your quant trading modelJuly 2025 Spike Watch & Low Risk High Win Rate Stock Picks - newser.com
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Newsfile
Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR)Contact Levi & Korsinsky Before December 8, 2025 - Stockhouse
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit - PR Newswire
aTyr Pharma, Inc. Class Action: Levi & Korsinsky Reminds aTyr Investors of the Pending ... - Bluefield Daily Telegraph
aTyr Pharma, Inc. Class Action: Levi & Korsinsky Reminds - GlobeNewswire
ATYR SHAREHOLDER ALERT: New aTyr Pharma, Inc. (ATYR) - GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar
ATYR DEADLINE: Faruqi & Faruqi Reminds aTyr Investors of the Pen - GuruFocus
ATYR DEADLINE: Faruqi & Faruqi Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025ATYR - MarketScreener
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders - WV News
Atyr Pharma Inc (ATYR) 財務データ
Atyr Pharma Inc (ATYR) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Atyr Pharma Inc (ATYR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
| Gross Jane A | Director |
Mar 17 '25 |
Buy |
4.00 |
3,750 |
15,000 |
9,750 |
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
1.38%
1.42%
大文字化:
|
ボリューム (24 時間):